A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

被引：0
|
作者：
Montesinos, Pau
Al-Ali, Haifa
Alonso-Dominguez, Juan M.
Jentzsch, Madlen
Jongen-Lavrencic, Mojca
Martelli, Maria Paola
Rollig, Christoph
Sica, Simona
Iadevaia, Riham
Yablonski, Kaitlin
Wang, Tianli
Mahmood, Zafar
Koenen, Giedre
Schmidt, Hank
Yang, Jingsong
Yee, Karen
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT124
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Treatment with imatinib mesylate in patients with refractory or relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or myeloproliferative disorders (MPD).
    Cortes, JE
    Giles, F
    O'Brien, S
    Talpaz, M
    Thomas, D
    Keating, M
    Garcia-Manero, G
    Faderl, S
    Estey, E
    Letvak, L
    Bochinski, K
    Kantarjian, H
    BLOOD, 2002, 100 (11) : 800A - 800A
  • [22] Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
    Metzeler, Klaus H.
    Winer, Eric S.
    Platzbecker, Uwe
    Verma, Amit
    DeAngelo, Daniel J.
    Tarantolo, Stefano R.
    Sallman, David A.
    Dugan, James
    Groepper, Stefanie
    Goetze, Katharina S.
    Li, Chia-Cheng
    Zhao, Wanying
    Lane, Maureen
    von Roemeling, Reinhard
    Carlisle, Samantha
    Weigert, Anne
    Boehme, Matthias
    Kubasch, Anne Sophie
    Garcia-Manero, Guillermo
    BLOOD, 2022, 140 : 9048 - 9049
  • [23] Perspectives of Patients With Relapsed and Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome on Patient-Clinician Communication About Prognosis and the Future
    Rao, Vinay
    Linsky, Sarah
    Knobf, M. Tish
    PALLIATIVE MEDICINE REPORTS, 2024, 5 (01): : 53 - 62
  • [24] Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
    Greenberg, PL
    Lee, SJ
    Advani, R
    Tallman, MS
    Sikic, BI
    Letendre, L
    Dugan, K
    Lum, B
    Chin, DL
    Dewald, G
    Paietta, E
    Bennett, JM
    Rowe, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1078 - 1086
  • [25] Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
    Zeidan, Amer M.
    DeAngelo, Daniel J.
    Palmer, Jeanne
    Seet, Christopher S.
    Tallman, Martin S.
    Wei, Xin
    Raymon, Heather
    Sriraman, Priya
    Kopytek, Stephan
    Bewersdorf, Jan Philipp
    Burgess, Michael R.
    Hege, Kristen
    Stock, Wendy
    ANNALS OF HEMATOLOGY, 2022, 101 (03) : 557 - 569
  • [26] Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
    Amer M. Zeidan
    Daniel J. DeAngelo
    Jeanne Palmer
    Christopher S. Seet
    Martin S. Tallman
    Xin Wei
    Heather Raymon
    Priya Sriraman
    Stephan Kopytek
    Jan Philipp Bewersdorf
    Michael R. Burgess
    Kristen Hege
    Wendy Stock
    Annals of Hematology, 2022, 101 : 557 - 569
  • [27] Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Zavras, Phaedon D. D.
    Sinanidis, Ilias
    Tsakiroglou, Panagiotis
    Karantanos, Theodoros
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [28] A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
    DiNardo, Courtney D.
    Strickland, Stephen Anthony
    Skikne, Barry
    Zeidan, Amer M.
    Traer, Elie
    Carraway, Hetty E.
    Frankel, Stanley
    Weiss, Daniel E.
    Wang, Jacky H.
    Pirie-Shepherd, Steven
    Piccotti, Joseph
    Wright, D. Hamish
    Akinsanya, Karen
    BLOOD, 2023, 142
  • [29] Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Mims, Alice S.
    Solh, Melhem
    Saultz, Jennifer N.
    Borate, Uma
    Pemmaraju, Naveen
    Borthakur, Gautam
    Roboz, Gail J.
    Powell, Ben
    Matusow, Bernice
    Halladay, Jason
    Vali, Shireen
    Hope, Chelsea L.
    Kundu, Madan G.
    Hsu, Ching
    Watkins, Paul
    Zhang, Chao
    Walling, Jackie M.
    Tsiatis, Athanasios C.
    DeZern, Amy E.
    BLOOD, 2021, 138
  • [30] Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
    Ivana Gojo
    Alexander Perl
    Selina Luger
    Maria R. Baer
    Kelly J. Norsworthy
    Kenneth S. Bauer
    Michael Tidwell
    Stephanie Fleckinger
    Martin Carroll
    Edward A. Sausville
    Investigational New Drugs, 2013, 31 : 1217 - 1227
12345